All Stories

  1. A Point-of-Care Raman Spectroscopy-Based Device for the Diagnosis of Gout and Pseudogout: Comparison With the Clinical Standard Microscopy
  2. Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis
  3. Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus
  4. Evaluation of musculoskeletal complaints in children
  5. Evaluation of musculoskeletal complaints in children
  6. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus
  7. Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy
  8. Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
  9. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
  10. Laser wavelength dependence of background fluorescence in Raman spectroscopic analysis of synovial fluid from symptomatic joints
  11. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review
  12. Tocilizumab in Pediatric Rheumatology: The Clinical Experience
  13. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
  14. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein
  15. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
  16. Do Adult Disease Severity Subclassifications Predict Use of Cyclophosphamide in Children with ANCA-associated Vasculitis? An Analysis of ARChiVe Study Treatment Decisions
  17. Increased Sensitivity of the European Medicines Agency Algorithm for Classification of Childhood Granulomatosis with Polyangiitis
  18. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
  19. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus
  20. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
  21. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology
  22. Use of atorvastatin in systemic lupus erythematosus in children and adolescents
  23. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus
  24. Mesenchymal Stem Cells: Mechanisms of Inflammation
  25. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
  26. Evaluation of musculoskeletal complaints in children
  27. Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort
  28. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT
  29. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measur
  30. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus
  31. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
  32. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: A secondary analysis of clinical trial data from children with Polyarticular-Cours...
  33. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood
  34. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity
  35. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis
  36. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort
  37. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
  38. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial
  39. Sjögren’s syndrome in childhood
  40. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis
  41. Rasmussen syndrome and CNS granulomatous disease with NOD2/CARD15 mutations
  42. CD166 Expression, Characterization, and Localization in Salivary Epithelium: Implications for Function During Sialoadenitis
  43. Critical Care Myopathy in a Child
  44. Remittive agents in pediatric rheumatology
  45. Evidence for the expression of a second CD6 ligand by synovial fibroblasts
  46. Prevention of infectious complications in rheumatic disease patients
  47. Update on immunosuppressive therapy
  48. Immunosuppressive drug treatment
  49. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on γ-interferon activated keratinocytes
  50. Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes
  51. Mouse CD6: sequence of cDNA and expression of mRNA
  52. Structures on the cell surface. Update from the fifth international workshop on human leukocyte differentiation antigens